Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

The provided article text is truncated after the headline and does not include trial results or supporting details. It states only that izalontamab brengitecan (Iza-Bren) doubled median progression-free survival in previously treated patients with EGFR-mutated non-small cell lung cancer; the comparator, numerical survival figures, and study context are not provided.